A CRN analysis found that Nvidia finished the first quarter with more than double the revenue of what Intel and AMD earned ...

The Detroit Lions ' running back duo of Jahmyr Gibbs and David Montgomery played well enough to receive new nicknames last ...

A massive insider purchase just hit Advanced Micro Devices (AMD), and it’s raising eyebrows across Wall Street. Philip Guido, ...

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

AMD (NASDAQ: AMD) isn't a bad company by any means, but if there was ever a company that could fit the saying, "always a ...

Here are the latest stock rating upgrades by Seeking Alpha analysts: Nvidia (NASDAQ:NVDA). Hold to buy by Hunting Alpha.

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

Rick Hwang, President of MiTAC Computing, emphasized the company's commitment to open innovation. By aligning with global ...

We recently published a list of 10 AI Stocks Making Waves This Week. In this article, we are going to take a look at where ...

A top executive at Advanced Micro Devices Inc. (NASDAQ: AMD) made a sizable open market purchase in the stock this week, ...